Ropes & Gray has advised Zenas BioPharma on the transaction, and Goodwin Procter and Maiwald GmbH have advised Royalty Pharma. Zenas BioPharma has entered into a...
Zenas BioPharma Secures Up to $300 Million Synthetic Royalty Financing from Royalty Pharma
Orionis Biosciences’ Collaboration with Genentech
Goodwin Procter advised Orionis Biosciences on the collaboration with Genentech. Privately held Orionis Biosciences announced a multi-year collaboration with Genentech, a member of the Roche Group, to discover...
Royalty Pharma’s Acquisition of Royalty Interest in SPINRAZA and Pelacarsen from Ionis
Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
Takeda’s Acquisition of NDI-034858 from Nimbus Therapeutics
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...